AstraZeneca Expects Vaccine Knowledge This Yr, Gross sales Beat Estimates

News18 Logo

AstraZeneca, the British drugmaker engaged on one of many world’s main COVID-19 vaccine candidates, on Thursday beat third-quarter gross sales estimates as demand for its various portfolio of medication remained robust throughout COVID-19 pandemic lockdowns, and it maintained its 2020 forecasts.

The corporate reiterated it anticipated outcomes from the late-stage trials on its experimental COVID-19 vaccine later this yr, relying on the speed of an infection amongst trial members.

Product gross sales, which exclude funds from collaborations, rose 7% to $6.52 billion for the three months ended Sept. 30 on a constant-currency foundation, forward of a company-compiled consensus of $6.50 billion.

Nonetheless, the corporate reported core earnings of 94 cents per share, decrease than analysts’ expectations of 98 cents.

Disclaimer: This put up has been auto-published from an company feed with none modifications to the textual content and has not been reviewed by an editor